Novo Nordisk A/S (NVO)
NYSE: NVO · IEX Real-Time Price · USD
124.51
-0.89 (-0.71%)
At close: Apr 12, 2024, 4:00 PM
124.36
-0.15 (-0.12%)
After-hours: Apr 12, 2024, 7:59 PM EDT

Company Description

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.

The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application.

The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S
Novo Nordisk logo
Country Denmark
Founded 1923
Industry Biotechnology
Sector Healthcare
Employees 64,319
CEO Lars Fruergaard Jorgensen

Contact Details

Address:
Novo Alle Dk 2880
Bagsvaerd Denmark, G7 00000
Denmark
Phone 4544448888
Website novonordisk.com

Stock Details

Ticker Symbol NVO
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000353278
CUSIP Number 670100205
ISIN Number US6701002056
SIC Code 2834

Key Executives

Name Position
Lars Fruergaard Jorgensen President, Chief Executive Officer and Member of Management Board
Karsten Munk Knudsen Executive Vice President, Chief Financial Officer and Member of the Management Board
Henrik Ehlers Wulff Executive Vice President of Product Supply, Quality and IT and Member of the Management Board
Camilla Sylvest Executive Vice President of Commercial Strategy and Corporate Affairs and Member of the Management Board
Dr. Martin Holst Lange Executive Vice President of Development and Member of the Management Board
Dr. Marcus Schindler Ph.D. Executive Vice President of Research and Early Development, Chief Scientific Officer & Member of the Management Board
Maziar Mike Doustdar Executive Vice President of International Operations and Member of the Management Board
Douglas J. Langa Executive Vice President of North America Operations and Member of Management Board
Ludovic Helfgott Executive Vice President, Head of Rare Disease and Member of Management Board
Tania Sabroe Executive Vice President of Global People and Organisation and Member of Management Board

Latest SEC Filings

Date Type Title
Apr 8, 2024 6-K Report of foreign issuer
Apr 2, 2024 6-K Report of foreign issuer
Apr 1, 2024 6-K Report of foreign issuer
Mar 25, 2024 6-K Report of foreign issuer
Mar 22, 2024 6-K Report of foreign issuer
Mar 21, 2024 6-K Report of foreign issuer
Mar 18, 2024 6-K Report of foreign issuer
Mar 11, 2024 6-K Report of foreign issuer
Mar 8, 2024 6-K Report of foreign issuer
Mar 5, 2024 6-K Report of foreign issuer